[Intralesional therapy using recombinant interferon alpha 2 B in lesions of the uterine cervix caused by human papilloma virus].
A clinical study on 20 patients with uterine cervix Human Papilloma Virus (HPV) lesions treated with intralesional recombinant alpha 2b interferon (3 millions I.U.) three times a week for three weeks where possible, is presented. After one year from treatment, lesions were cured or stabilized in 18 Patients (90%); progression was observed in 2 patients (10%) for which reason traditional surgical therapy was performed.